Getting a new technology out of the laboratory and into the market is not easy. Proving that something works is only the first step. Companies also have to find customers who need it, figure out what they are willing to pay, and find a practical way to produce it. In areas such as advanced materials and climate technology, the move from research to production can bring even more challenges.
A good technology also needs a good business plan behind it. Manufacturing costs, intellectual property, funding, partnerships, and customer demand all matter once an idea moves beyond the lab. What works on a small scale may not always work when production increases, so companies have to be prepared to adapt along the way.
Everett E. Carpenter, CEO of Evertechnologies LLC, has experience working through these challenges as technologies move toward commercialization. His work covers scientific research, business development, manufacturing scale-up, funding, intellectual property, and partnerships.
In this Q&A, Carpenter talks about what he has learned from helping startups and new technologies move from an early idea toward the market.
1. How do you translate complex scientific and technical concepts into scalable, market-ready solutions?
I begin by separating what is scientifically interesting from what is commercially essential. A technology may have dozens of remarkable attributes, but customers may care deeply about only two or three. Identifying those attributes changes how you approach product development.
From there, I work backward from the desired commercial outcome. What performance does the customer require? What price creates a compelling value proposition? What volume must be produced? What regulatory, supply-chain, or installation constraints exist? These requirements become design parameters for both the product and manufacturing process.
This is particularly important with advanced materials. The objective is not to preserve every detail of the laboratory process, but to preserve the characteristics responsible for customer value while developing a simpler, repeatable, and economically scalable way to manufacture them.
Successful commercialization is therefore an exercise in translation: translating science into performance, performance into customer value, and customer value into a sustainable business model.
2. What has been your approach to guiding startups from minimum viable concepts through to successful market entry?
I encourage startups to treat the minimum viable concept as the beginning of a learning process rather than a miniature version of the final product.
At that stage, the most valuable outcome is information. Does the technology solve the problem we believe it solves? Does the customer value it enough to change behavior or spend money? Can the company manufacture it at an acceptable cost? What assumptions remain untested?
As evidence accumulates, investment should become more deliberate. Manufacturing capacity, staffing, intellectual property, partnerships, and market-entry spending should grow in response to validated milestones rather than optimism alone.
I also encourage founders to preserve optionality. Early companies rarely have enough information to know which market, business model, or manufacturing structure will ultimately be optimal. The goal is to learn quickly without making irreversible commitments too early.
3. How do you ensure intellectual property is effectively safeguarded during commercialization and scaling processes?
I approach intellectual property by asking a different question from simply, “What can we patent?”
The more important question is: What advantage are we trying to prevent a competitor from reproducing? Sometimes that advantage is the material itself. In other situations, it is a manufacturing process, formulation, equipment configuration, application, or accumulated process knowledge that may be better protected as a trade secret.
Scale-up is especially important because manufacturing development often creates valuable intellectual property that did not exist during the original invention. New operating windows, process controls, cost reductions, and production methods can strengthen the competitive position.
For that reason, IP strategy should evolve alongside commercialization. Intellectual property is most valuable when it protects the economic advantage of the business, not merely the novelty of the original invention.
4. What strategies have proven most effective in securing funding from federal, state, and private sources?
Funding becomes easier to navigate when companies understand that different capital sources are designed to answer different questions.
Federal and state programs can help reduce technical risk, demonstrate feasibility, and advance technologies before traditional investors are prepared to accept that risk. Strategic corporate partners may provide capital because a technology solves a specific business problem or strengthens their product pipeline. Equity investors generally need evidence that the opportunity can scale and generate an attractive return.
I therefore encourage companies to build a funding architecture rather than simply “raise money.” Match the source of capital to the risk being retired.
My experience with federal programs, non-dilutive funding, joint-development agreements, and private investment has reinforced that the strongest funding strategy is often a sequence of complementary sources rather than dependence on one investor or program.
5. How do you foster and manage strategic partnerships with policymakers, incubators, and industry stakeholders?
Effective partnerships begin by understanding what success means to the other party. A startup may want capital, while a manufacturer may seek access to a new product or a government agency may focus on economic development. These goals may overlap, but they are not identical.
My approach is to find where those interests intersect and build the partnership around shared value. I also believe good partnerships require candor. Identifying conflicting expectations early can prevent problems later.
Working across universities, federal agencies, incubators, startups, and major corporations has taught me that lasting partnerships are built on more than transactions. They succeed because each organization brings something the others cannot easily create themselves.
6. What challenges have you encountered in manufacturing scale-up within climate technology and advanced materials sectors?
One fundamental challenge is that advanced materials frequently behave differently when production increases by orders of magnitude.
Heat transfer changes. Mixing changes. Reaction kinetics change. Raw-material variability becomes more important. Equipment geometry matters. Quality specifications that were easily controlled in a small laboratory batch can become significant manufacturing challenges.
Climate technology adds another constraint: economics. A sustainable technology that cannot compete economically will struggle to create environmental impact at meaningful scale.
I therefore prefer to design scale-up around the required economics as well as the required performance. Sometimes the technically elegant process is not the commercially appropriate one.
The best manufacturing solution is not necessarily the most sophisticated. It is the process that repeatedly produces the performance customers require, at the volume they need, at economics that allow adoption to grow.
7. How do you balance investor expectations with operational realities and long-term business objectives?
I believe the best way to manage investor expectations is to replace broad promises with measurable milestones. Investors understand that advanced-technology companies face uncertainty. What matters is explaining what must be learned next, what it will cost, and what decision will follow.
I prefer to connect capital to specific milestones such as technical validation, customer qualification, manufacturing cost reduction, production capacity, intellectual-property protection, or market entry.
This creates a common language between investors and operators. Long-term strategy matters, but credibility is built one completed milestone at a time.
“Successful commercialization begins where science meets customer value.”
